Gene Therapy Clinical Trials
Stanford Accelerated Recovery Trial (START)
The goal of this study is to determine whether administering Gabapentin prior to surgery affects duration of pain and opioid use post-surgery. The investigators aim to compare gabapentin to placebo in a prospective, randomized clinical trial in which patients will be followed post-surgery until pain resolves and opioid use ceases.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Gabapentin
- drug: Lorazepam (active control)
- drug: Placebo (inactive)
Eligibility
INCLUSION CRITERIA
- Age 18 to 75
- Undergoing a scheduled surgery
- English speaking
- Ability and willingness to complete questionnaires or use Palm Pilot
EXCLUSION CRITERIA
- Known kidney disease
- Currently receiving gabapentin or (pregabalin) lyrica already
- Cognitive impairment
- Previous history of excessive sedation or adverse reaction to gabapentin (not it was
tried but ineffective for nerve pain)
- Coexisting chronic pain > 4/10 disorder in area other than surgical target
- Plan to move out of state
- Condition that would in judgment of team member make patient likely to be lost to
follow-up
- Elevated suicidality
- Known pregnancy
- Current symptoms of ataxia, dizziness, or sedation
- Narrow angle glaucoma
- Severe respiratory insufficiency (ie, severe emphysema or chronic obstructive
pulmonary disease)
- History of gastric bypass surgery and obstructive sleep apnea requiring continuous
positive airway pressure (CPAP)
Ages Eligible for Study
18 Years - 75 Years
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
ccto-office@stanford.edu
650-498-7061
Not Recruiting